Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease

Francesco Panza, Vincenza Frisardi, Cristiano Capurso, Alessia D'Introno, Anna M. Colacicco, Gianluigi Vendemiale, Antonio Capurso, Vincenzo Solfrizzi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Very recent findings confirmed that S-adenosylmethionine (SAM) can exert a direct effect on glutathione S-transferase (GST) activity. Alzheimer's disease (AD) is accompanied by reduced GST activity, diminished SAM, and increased S-adenosyl homocysteine (SAH), the downstream metabolic product resulting from SAM-mediated transmethylation reactions, when deprived of folate. Therefore, these findings underscored the critical role of SAM in maintenance of neuronal health, suggesting a possible role of SAM as a neuroprotective dietary supplement in AD. Given recent findings from clinical trials in which ω-3 polyunsturated fatty acids (PUFA) supplementation was effective only in very mild AD subgroups or mild cognitive impairment (MCI), we suggest intervention trials using measures of dietary supplementation (dietary ω-3 PUFA and SAM plus B vitamin supplementation) to determine if such supplements will reduce the risk for cognitive decline in very mild AD and MCI. Therefore, key supplements are not necessarily working in isolation, and the most profound impact, or in some cases the only impact, is noted very early in the course of AD, suggesting that nutriceutical supplements may bolster pharmacological approaches well past the window where supplements can work on their own.

Original languageEnglish
Pages (from-to)467-470
Number of pages4
JournalJournal of Alzheimer's Disease
Volume16
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

S-Adenosylhomocysteine
S-Adenosylmethionine
Unsaturated Fatty Acids
Alzheimer Disease
Dietary Supplements
Glutathione Transferase
Fatty Acids
Vitamin B Complex
Homocysteine
Folic Acid
Glutathione
Clinical Trials
Pharmacology
Health

Keywords

  • ω-3 polyunsturated fatty acids
  • Alzheimer's disease
  • Mild cognitive impairment
  • S-Adenosylhomocysteine
  • S-Adenosylmethionine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease. / Panza, Francesco; Frisardi, Vincenza; Capurso, Cristiano; D'Introno, Alessia; Colacicco, Anna M.; Vendemiale, Gianluigi; Capurso, Antonio; Solfrizzi, Vincenzo.

In: Journal of Alzheimer's Disease, Vol. 16, No. 3, 2009, p. 467-470.

Research output: Contribution to journalArticle

Panza, F, Frisardi, V, Capurso, C, D'Introno, A, Colacicco, AM, Vendemiale, G, Capurso, A & Solfrizzi, V 2009, 'Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease', Journal of Alzheimer's Disease, vol. 16, no. 3, pp. 467-470. https://doi.org/10.3233/JAD-2009-1012
Panza, Francesco ; Frisardi, Vincenza ; Capurso, Cristiano ; D'Introno, Alessia ; Colacicco, Anna M. ; Vendemiale, Gianluigi ; Capurso, Antonio ; Solfrizzi, Vincenzo. / Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease. In: Journal of Alzheimer's Disease. 2009 ; Vol. 16, No. 3. pp. 467-470.
@article{9600667af44546d9814e873406a57050,
title = "Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease",
abstract = "Very recent findings confirmed that S-adenosylmethionine (SAM) can exert a direct effect on glutathione S-transferase (GST) activity. Alzheimer's disease (AD) is accompanied by reduced GST activity, diminished SAM, and increased S-adenosyl homocysteine (SAH), the downstream metabolic product resulting from SAM-mediated transmethylation reactions, when deprived of folate. Therefore, these findings underscored the critical role of SAM in maintenance of neuronal health, suggesting a possible role of SAM as a neuroprotective dietary supplement in AD. Given recent findings from clinical trials in which ω-3 polyunsturated fatty acids (PUFA) supplementation was effective only in very mild AD subgroups or mild cognitive impairment (MCI), we suggest intervention trials using measures of dietary supplementation (dietary ω-3 PUFA and SAM plus B vitamin supplementation) to determine if such supplements will reduce the risk for cognitive decline in very mild AD and MCI. Therefore, key supplements are not necessarily working in isolation, and the most profound impact, or in some cases the only impact, is noted very early in the course of AD, suggesting that nutriceutical supplements may bolster pharmacological approaches well past the window where supplements can work on their own.",
keywords = "ω-3 polyunsturated fatty acids, Alzheimer's disease, Mild cognitive impairment, S-Adenosylhomocysteine, S-Adenosylmethionine",
author = "Francesco Panza and Vincenza Frisardi and Cristiano Capurso and Alessia D'Introno and Colacicco, {Anna M.} and Gianluigi Vendemiale and Antonio Capurso and Vincenzo Solfrizzi",
year = "2009",
doi = "10.3233/JAD-2009-1012",
language = "English",
volume = "16",
pages = "467--470",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and alzheimer's disease

AU - Panza, Francesco

AU - Frisardi, Vincenza

AU - Capurso, Cristiano

AU - D'Introno, Alessia

AU - Colacicco, Anna M.

AU - Vendemiale, Gianluigi

AU - Capurso, Antonio

AU - Solfrizzi, Vincenzo

PY - 2009

Y1 - 2009

N2 - Very recent findings confirmed that S-adenosylmethionine (SAM) can exert a direct effect on glutathione S-transferase (GST) activity. Alzheimer's disease (AD) is accompanied by reduced GST activity, diminished SAM, and increased S-adenosyl homocysteine (SAH), the downstream metabolic product resulting from SAM-mediated transmethylation reactions, when deprived of folate. Therefore, these findings underscored the critical role of SAM in maintenance of neuronal health, suggesting a possible role of SAM as a neuroprotective dietary supplement in AD. Given recent findings from clinical trials in which ω-3 polyunsturated fatty acids (PUFA) supplementation was effective only in very mild AD subgroups or mild cognitive impairment (MCI), we suggest intervention trials using measures of dietary supplementation (dietary ω-3 PUFA and SAM plus B vitamin supplementation) to determine if such supplements will reduce the risk for cognitive decline in very mild AD and MCI. Therefore, key supplements are not necessarily working in isolation, and the most profound impact, or in some cases the only impact, is noted very early in the course of AD, suggesting that nutriceutical supplements may bolster pharmacological approaches well past the window where supplements can work on their own.

AB - Very recent findings confirmed that S-adenosylmethionine (SAM) can exert a direct effect on glutathione S-transferase (GST) activity. Alzheimer's disease (AD) is accompanied by reduced GST activity, diminished SAM, and increased S-adenosyl homocysteine (SAH), the downstream metabolic product resulting from SAM-mediated transmethylation reactions, when deprived of folate. Therefore, these findings underscored the critical role of SAM in maintenance of neuronal health, suggesting a possible role of SAM as a neuroprotective dietary supplement in AD. Given recent findings from clinical trials in which ω-3 polyunsturated fatty acids (PUFA) supplementation was effective only in very mild AD subgroups or mild cognitive impairment (MCI), we suggest intervention trials using measures of dietary supplementation (dietary ω-3 PUFA and SAM plus B vitamin supplementation) to determine if such supplements will reduce the risk for cognitive decline in very mild AD and MCI. Therefore, key supplements are not necessarily working in isolation, and the most profound impact, or in some cases the only impact, is noted very early in the course of AD, suggesting that nutriceutical supplements may bolster pharmacological approaches well past the window where supplements can work on their own.

KW - ω-3 polyunsturated fatty acids

KW - Alzheimer's disease

KW - Mild cognitive impairment

KW - S-Adenosylhomocysteine

KW - S-Adenosylmethionine

UR - http://www.scopus.com/inward/record.url?scp=65549120331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549120331&partnerID=8YFLogxK

U2 - 10.3233/JAD-2009-1012

DO - 10.3233/JAD-2009-1012

M3 - Article

C2 - 19276539

AN - SCOPUS:65549120331

VL - 16

SP - 467

EP - 470

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -